Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 146.90
-4.10 (-2.72%)
Apr 20, 2026, 4:08 PM HKT
Akeso Revenue
In the year 2025, Akeso had annual revenue of 3.06B CNY with 43.90% growth. Akeso had revenue of 1.64B in the half year ending December 31, 2025, with 93.64% growth.
Revenue
3.06B CNY
Revenue Growth
+43.90%
P/S Ratio
39.79
Revenue / Employee
812.62K CNY
Employees
3,761
Market Cap
135.32B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.06B | 932.33M | 43.90% |
| Dec 31, 2024 | 2.12B | -2.40B | -53.08% |
| Dec 31, 2023 | 4.53B | 3.69B | 440.35% |
| Dec 31, 2022 | 837.66M | 612.03M | 271.26% |
| Dec 31, 2021 | 225.63M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 41.59B |
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.62B |
| Shanghai Junshi Biosciences | 2.78B |
Akeso News
- 10 days ago - China healthcare stocks outgain Hong Kong market as Middle East roils global investments - South China Morning Post
- 11 days ago - Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Benzinga
- 13 days ago - Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026 - PRNewsWire
- 24 days ago - Akeso Reports Full-Year 2025 Financial Results - PRNewsWire
- 26 days ago - Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab - PRNewsWire
- 5 weeks ago - Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance - PRNewsWire
- 6 weeks ago - Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results - PRNewsWire
- 2 months ago - Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications - PRNewsWire